大规模现场随机试验证明LetiFend®疫苗对犬利什曼原虫病的安全性和有效性
这项多中心、随机、双盲、安慰剂对照现场试验在法国和西班牙纳入549只犬,每年单次皮下接种LetiFend®或安慰剂,自然暴露两个婴儿利什曼原虫传播季。疫苗耐受良好,显著降低利什曼病相关临床症状发生率, confirmed病例数在疫苗组统计学显著更低,总体效力72%。
要点
- LetiFend®疫苗在 endemic 区大规模犬群中耐受良好并显著降低利什曼病相关临床症状发生率。
- 疫苗组 confirmed 利什曼病病例数统计学显著低于安慰剂组,总体效力72%。
- 疫苗组带虫犬数接近显著减少(p=0.0564),血清阳性犬再接种安全且不加重病程。
核心结论
- 本现场试验表明LetiFend®是一种新型、安全有效的疫苗,可用于6月龄以上未感染犬的主动免疫,降低自然感染婴儿利什曼原虫后发生临床利什曼病的风险。
研究设计与样本
- 多中心、随机、双盲、安慰剂对照现场试验,纳入法国和西班牙549只不同性别、品种和年龄的犬,每年单次皮下接种LetiFend®或安慰剂,自然暴露两个婴儿利什曼原虫传播季。
主要发现
- LetiFend®耐受良好并明显降低利什曼病相关临床症状发生率。
- 疫苗组 confirmed 利什曼病病例数统计学显著低于安慰剂组。
- 疫苗组带虫犬数接近显著减少(p=0.0564)。
- 血清阳性犬再接种安全且不加重病程。
- 在高疾病压力地区,接种LetiFend®的犬发生 confirmed 病例或利什曼病临床症状的可能性分别比未接种犬低5倍和9.8倍,总体效力72%。
临床怎么用
- 原文结论认为LetiFend®可用于6月龄以上未感染犬的主动免疫以降低自然感染后发生临床利什曼病的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Canine leishmaniosis is a zoonotic disease caused by Leishmania infantum. Extensive research is currently ongoing to develop safe and effective vaccines to protect from disease development. The European Commission has granted a marketing authorization for LetiFend®, a new vaccine containing recombinant Protein Q. The efficacy of LetiFend® vaccination in a large-scale dog population of both sexes, different breeds and ages in endemic areas is reported in this multicenter, randomized, double-blind, placebo-controlled field trial. Dogs (n = 549) living in France and Spain were randomly selected to receive a single subcutaneous dose of LetiFend® or placebo per year, and were naturally exposed to two L. infantum transmission seasons. Clinical examinations, blood and lymphoid organ sampling to evaluate serological, parasitological and disease status of the dogs were performed at different time points during the study. LetiFend® was very well tolerated and clearly reduced the incidence of clinical signs related to leishmaniosis. The number of confirmed cases of leishmaniosis was statistically significantly lower in the vaccine group. The number of dogs with parasites was close to be significantly reduced in the vaccine group (p = 0.0564). Re-vaccination of seropositive dogs demonstrated to be safe and not to worsen the course of the disease. The likelihood that a dog vaccinated with LetiFend® develops a confirmed case or clinical signs of leishmaniosis in areas with high pressure is, respectively, 5 and 9.8 time less than that for an unvaccinated dog. Thus, the overall efficacy of the LetiFend® vaccine in the prevention of confirmed cases of leishmaniosis in endemic areas with high disease pressure was shown to be 72%. In conclusion, this field trial demonstrates that LetiFend® is a novel, safe and effective vaccine for the active immunization of non-infected dogs from 6 months of age in reducing the risk of developing clinical leishmaniosis after natural infection with Leishmania infantum.
引用
- Fernández Cotrina J, Iniesta V, Monroy I, et al. A large-scale field randomized trial demonstrates safety and efficacy of the vaccine LetiFend® against canine leishmaniosis. Vaccine. 2018. PMID: 29525281. doi:10.1016/j.vaccine.2018.02.111
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。